ImpactLogo2Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) is the most widely used and scientifically validated computerized cognitive assessment tool available for concussion management. ImPACT is also the first medical device of its kind to receive U.S. Food and Drug Administration (FDA) de novo clearance. FDA clearance has been granted under Computerized Cognitive Assessment Aid for Concussion, a new category for a device that uses an individual’s score(s) on a battery of cognitive tasks to provide an indication of the current level of cognitive function in response to concussion. FDA de novo clearance signifies ImPACT has met the FDA’s premarket requirements to demonstrate accuracy, validity, and reliability for concussion management and specifically states that ImPACT will “aid in the assessment and management of concussion.” Developed by two doctors in the early 1990’s, Mark Lovell, PhD, and Joseph Maroon, MD, ImPACT has become the gold standard computerized test for athletes in both amateur and professional sport. ImPACT Applications, Inc. was co-founded by Drs Mark Lovell, PhD, Joseph Maroon, MD, and Michael (Micky) Collins, PhD.

The comprehensive ImPACT system was designed to help qualified practitioners properly manage concussive injuries and assist in return to play recommendations. The test battery takes approximately 20 minutes to complete, and measures several important cognitive functions including:

  • Attention span
  • Working memory
  • Sustained and selective attention time
  • Response variability
  • Non-verbal problem solving
  • Reaction time (measured to 1/100th of a second)

Though not used as a stand-alone tool, ImPACT is an integral component to concussion management and rehabilitation. For more information please visit the ImPACT website at